Sionna Therapeutics (SION) Stock Analysis & Winston Score
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (1/20)
- Cash Flow: Data not available (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $49.41
Market Cap: $2.2B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

